Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice

S. Shimizu, H. Nakashima, K. Masutani, Y. Inoue, K. Miyake, M. Akahoshi, Y. Tanaka, K. Egashira, H. Hirakata, T. Otsuka, M. Harada

研究成果: ジャーナルへの寄稿記事

76 引用 (Scopus)

抄録

Objective. Monocyte chemoattractant protein-1 (MCP-1) is up-regulated and recruits and activates inflammatory cells in human diffuse proliferative lupus nephritis (DPLN) and in nephritis of lupus model MRL/lpr mice. The aim of this study was to examine whether anti-MCP-1 gene therapy inhibits the progression of nephritis in MRL/lpr mice. Method. An NH2-terminal deletion mutant of the MCP-1 gene, 7ND, was injected into skeletal muscles of MRL/lpr mice with advanced stage nephritis to blockade MCP-1 and its receptor (CCR2) signalling pathway. Result. Histological findings of kidneys in treated mice, which received more than four injections of 7ND, showed that protection against renal injury resulted from reduced infiltration of leucocytes. Therefore, this therapy has been shown to prolong the life span of MRL/lpr mice. Conclusion. Anti-MCP-1 gene therapy is specifically effective in the localized inflammatory region. The data presented here indicate that this anti-MCP-1 gene therapy may be effective adjunct in the management of DPLN.

元の言語英語
ページ(範囲)1121-1128
ページ数8
ジャーナルRheumatology
43
発行部数9
DOI
出版物ステータス出版済み - 9 1 2004

Fingerprint

Inbred MRL lpr Mouse
Nephritis
Chemokine CCL2
Genetic Therapy
Lupus Nephritis
CCR2 Receptors
Kidney
Skeletal Muscle
Leukocytes
Injections
Wounds and Injuries
Genes

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

これを引用

Shimizu, S., Nakashima, H., Masutani, K., Inoue, Y., Miyake, K., Akahoshi, M., ... Harada, M. (2004). Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology, 43(9), 1121-1128. https://doi.org/10.1093/rheumatology/keh277

Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. / Shimizu, S.; Nakashima, H.; Masutani, K.; Inoue, Y.; Miyake, K.; Akahoshi, M.; Tanaka, Y.; Egashira, K.; Hirakata, H.; Otsuka, T.; Harada, M.

:: Rheumatology, 巻 43, 番号 9, 01.09.2004, p. 1121-1128.

研究成果: ジャーナルへの寄稿記事

Shimizu, S, Nakashima, H, Masutani, K, Inoue, Y, Miyake, K, Akahoshi, M, Tanaka, Y, Egashira, K, Hirakata, H, Otsuka, T & Harada, M 2004, 'Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice', Rheumatology, 巻. 43, 番号 9, pp. 1121-1128. https://doi.org/10.1093/rheumatology/keh277
Shimizu, S. ; Nakashima, H. ; Masutani, K. ; Inoue, Y. ; Miyake, K. ; Akahoshi, M. ; Tanaka, Y. ; Egashira, K. ; Hirakata, H. ; Otsuka, T. ; Harada, M. / Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. :: Rheumatology. 2004 ; 巻 43, 番号 9. pp. 1121-1128.
@article{1b5296217f4e4b1a8d3e34a98e51bc49,
title = "Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice",
abstract = "Objective. Monocyte chemoattractant protein-1 (MCP-1) is up-regulated and recruits and activates inflammatory cells in human diffuse proliferative lupus nephritis (DPLN) and in nephritis of lupus model MRL/lpr mice. The aim of this study was to examine whether anti-MCP-1 gene therapy inhibits the progression of nephritis in MRL/lpr mice. Method. An NH2-terminal deletion mutant of the MCP-1 gene, 7ND, was injected into skeletal muscles of MRL/lpr mice with advanced stage nephritis to blockade MCP-1 and its receptor (CCR2) signalling pathway. Result. Histological findings of kidneys in treated mice, which received more than four injections of 7ND, showed that protection against renal injury resulted from reduced infiltration of leucocytes. Therefore, this therapy has been shown to prolong the life span of MRL/lpr mice. Conclusion. Anti-MCP-1 gene therapy is specifically effective in the localized inflammatory region. The data presented here indicate that this anti-MCP-1 gene therapy may be effective adjunct in the management of DPLN.",
author = "S. Shimizu and H. Nakashima and K. Masutani and Y. Inoue and K. Miyake and M. Akahoshi and Y. Tanaka and K. Egashira and H. Hirakata and T. Otsuka and M. Harada",
year = "2004",
month = "9",
day = "1",
doi = "10.1093/rheumatology/keh277",
language = "English",
volume = "43",
pages = "1121--1128",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice

AU - Shimizu, S.

AU - Nakashima, H.

AU - Masutani, K.

AU - Inoue, Y.

AU - Miyake, K.

AU - Akahoshi, M.

AU - Tanaka, Y.

AU - Egashira, K.

AU - Hirakata, H.

AU - Otsuka, T.

AU - Harada, M.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Objective. Monocyte chemoattractant protein-1 (MCP-1) is up-regulated and recruits and activates inflammatory cells in human diffuse proliferative lupus nephritis (DPLN) and in nephritis of lupus model MRL/lpr mice. The aim of this study was to examine whether anti-MCP-1 gene therapy inhibits the progression of nephritis in MRL/lpr mice. Method. An NH2-terminal deletion mutant of the MCP-1 gene, 7ND, was injected into skeletal muscles of MRL/lpr mice with advanced stage nephritis to blockade MCP-1 and its receptor (CCR2) signalling pathway. Result. Histological findings of kidneys in treated mice, which received more than four injections of 7ND, showed that protection against renal injury resulted from reduced infiltration of leucocytes. Therefore, this therapy has been shown to prolong the life span of MRL/lpr mice. Conclusion. Anti-MCP-1 gene therapy is specifically effective in the localized inflammatory region. The data presented here indicate that this anti-MCP-1 gene therapy may be effective adjunct in the management of DPLN.

AB - Objective. Monocyte chemoattractant protein-1 (MCP-1) is up-regulated and recruits and activates inflammatory cells in human diffuse proliferative lupus nephritis (DPLN) and in nephritis of lupus model MRL/lpr mice. The aim of this study was to examine whether anti-MCP-1 gene therapy inhibits the progression of nephritis in MRL/lpr mice. Method. An NH2-terminal deletion mutant of the MCP-1 gene, 7ND, was injected into skeletal muscles of MRL/lpr mice with advanced stage nephritis to blockade MCP-1 and its receptor (CCR2) signalling pathway. Result. Histological findings of kidneys in treated mice, which received more than four injections of 7ND, showed that protection against renal injury resulted from reduced infiltration of leucocytes. Therefore, this therapy has been shown to prolong the life span of MRL/lpr mice. Conclusion. Anti-MCP-1 gene therapy is specifically effective in the localized inflammatory region. The data presented here indicate that this anti-MCP-1 gene therapy may be effective adjunct in the management of DPLN.

UR - http://www.scopus.com/inward/record.url?scp=4544266604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544266604&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keh277

DO - 10.1093/rheumatology/keh277

M3 - Article

C2 - 15213333

AN - SCOPUS:4544266604

VL - 43

SP - 1121

EP - 1128

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 9

ER -